[TOLERANCE OF 2-BENZENESULFONAMIDO-5-(2-METHOXYETHOXY)-PYRIMIDINE (GLYCODIAZIN) IN LONG-TERM ADMINISTRATION IN ANIMAL EXPERIMENTS].
D000380:Agranulocytosis; D032761:Animal Experimentation; D000818:Animals; D001855:Bone Marrow Diseases; D000013:Congenital Abnormalities; D004285:Dogs; D004361:Drug Tolerance; D006413:Hematopoietic System; D007004:Hypoglycemic Agents; D051379:Mice; D011743:Pyrimidines; D051381:Rats; D012106:Research; D013449:Sulfonamides; D014116:Toxicology
D007004:Hypoglycemic Agents; D011743:Pyrimidines; D013449:Sulfonamides; C030986:pyrimidine
ABNORMALITIES; AGRANULOCYTOSIS; ANTIDIABETICS; BONE MARROW DISEASES; DOGS; DRUG TOLERANCE; EXPERIMENTAL LAB STUDY; HEMATOPOIETIC SYSTEM; MICE; PYRIMIDINES; RATS; SULFONAMIDES; TOXICOLOGIC REPORT
VERTRAEGLICHKEIT VON 2-BENZOLSULFONAMIDO-5(BETA-METHOXY-AETHOXY)-PYRIMIDIN (GLYCODIAZIN) BEI LANGDAUERNDER VERABREICHUNG IM TIERVERSUCH.